Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.79 |
| ▸ | CSF1R | P07333 | 1/20 | 0.76 |
| ▸ | NAMPT | P43490 | 3/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.70 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GALR2 | O43603 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661935 | 1.00 | BRAF (0.79) | BRAFCSF1RNAMPTNT5EKCNK3 | |
| SCHEMBL12411961 | 0.91 | BRAF (0.71) | BRAFCSF1RNAMPTNT5EKCNK3 | |
| SCHEMBL30533390 | 0.89 | LMNA (0.81) | NAMPTKCNK3LMNAHIF1AALDH1A1 | |
| SCHEMBL3937779 | 0.89 | BRAF (1.00) | BRAFCSF1RKCNK3KCNK9 | |
| SCHEMBL259177 | 0.88 | TDP1 (0.78) | BRAFCSF1RNAMPTKCNK3KCNK9 | |
| SCHEMBL3935559 | 0.87 | BRAF (0.80) | BRAFCSF1RKCNK3KCNK9 | |
| SCHEMBL3941840 | 0.87 | CSF1R (1.00) | BRAFCSF1RKCNK3KCNK9NPC1 | |
| SCHEMBL790322 | 0.85 | NAMPT (0.71) | BRAFCSF1RNAMPTLMNAHIF1A | |
| SCHEMBL14210406 | 0.85 | SIRT2 (0.72) | BRAFCSF1RNAMPTLMNAHIF1A | |
| SCHEMBL19662798 | 0.85 | NT5E (0.70) | BRAFCSF1RNT5EKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464286-B1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2021-08-18 | — | — | EP | disclosed |
| WO-2017205538-A1 | PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | BRAF 4097/4885CSF1R 949/4885NAMPT 2446/4885 |
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | BRAF 1296/4885CSF1R 4775/4885NAMPT 169/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | BRAF 1296/4885CSF1R 4775/4885NAMPT 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.